GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Common Stock

CTOR (Citius Oncology) Common Stock : $0.01 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Common Stock?

Citius Oncology's quarterly common stock stayed the same from Sep. 2022 ($0.01 Mil) to Sep. 2023 ($0.01 Mil) and stayed the same from Sep. 2023 ($0.01 Mil) to Sep. 2024 ($0.01 Mil).

Citius Oncology's annual common stock stayed the same from Sep. 2022 ($0.01 Mil) to Sep. 2023 ($0.01 Mil) and stayed the same from Sep. 2023 ($0.01 Mil) to Sep. 2024 ($0.01 Mil).

Citius Oncology Common Stock Historical Data

The historical data trend for Citius Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Common Stock Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Common Stock
0.01 0.01 0.01

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Common Stock 0.01 0.01 0.01

Citius Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Common Stock
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.